Irhythm Technologies, Inc. (IRTC)

$67.2

+1.99

(+3.05%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $61.98
    $67.44
    $67.20
    downward going graph

    7.77%

    Downside

    Day's Volatility :8.1%

    Upside

    0.36%

    downward going graph
  • $60.88
    $124.12
    $67.20
    downward going graph

    9.4%

    Downside

    52 Weeks Volatility :50.95%

    Upside

    45.86%

    downward going graph

Returns

PeriodIrhythm Technologies, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-29.36%
5.1%
0.0%
6 Months
-39.82%
5.1%
0.0%
1 Year
-30.2%
16.6%
0.0%
3 Years
41.32%
13.2%
-21.4%

Highlights

Market Capitalization
2.1B
Book Value
$3.18
Earnings Per Share (EPS)
-4.27
PEG Ratio
0.0
Wall Street Target Price
119.3
Profit Margin
-24.5%
Operating Margin TTM
-15.52%
Return On Assets TTM
-9.36%
Return On Equity TTM
-81.46%
Revenue TTM
537.1M
Revenue Per Share TTM
17.4
Quarterly Revenue Growth YOY
19.3%
Gross Profit TTM
281.6M
EBITDA
-95.8M
Diluted Eps TTM
-4.27
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.74
EPS Estimate Next Year
-1.91
EPS Estimate Current Quarter
-0.89
EPS Estimate Next Quarter
-0.58

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 18 Wall street analysts offering stock ratings for Irhythm Technologies, Inc.(by analysts ranked 0 to 5 stars)
Based on 18 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
16
16
16
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 77.53%

Current $67.20
Target $119.30

Company Financials

FY18Y/Y Change
Revenue
147.3M
↑ 49.52%
Net Income
-48.3M
↑ 64.11%
Net Profit Margin
-32.78%
↓ 2.91%
FY19Y/Y Change
Revenue
214.6M
↑ 45.66%
Net Income
-54.6M
↑ 13.02%
Net Profit Margin
-25.43%
↑ 7.35%
FY20Y/Y Change
Revenue
265.2M
↑ 23.59%
Net Income
-43.8M
↓ 19.68%
Net Profit Margin
-16.53%
↑ 8.9%
FY21Y/Y Change
Revenue
322.8M
↑ 21.74%
Net Income
-101.4M
↑ 131.26%
Net Profit Margin
-31.4%
↓ 14.87%
FY22Y/Y Change
Revenue
410.9M
↑ 27.29%
Net Income
-116.2M
↑ 14.6%
Net Profit Margin
-28.27%
↑ 3.13%
FY23Y/Y Change
Revenue
492.7M
↑ 19.9%
Net Income
-123.4M
↑ 6.24%
Net Profit Margin
-25.05%
↑ 3.22%
Q1 FY23Q/Q Change
Revenue
111.4M
↓ 1.05%
Net Income
-39.1M
↑ 93.63%
Net Profit Margin
-35.1%
↓ 17.16%
Q2 FY23Q/Q Change
Revenue
124.1M
↑ 11.39%
Net Income
-18.5M
↓ 52.74%
Net Profit Margin
-14.89%
↑ 20.21%
Q3 FY23Q/Q Change
Revenue
124.6M
↑ 0.38%
Net Income
-27.1M
↑ 46.72%
Net Profit Margin
-21.76%
↓ 6.87%
Q4 FY23Q/Q Change
Revenue
132.5M
↑ 6.35%
Net Income
-38.7M
↑ 42.72%
Net Profit Margin
-29.2%
↓ 7.44%
Q1 FY24Q/Q Change
Revenue
131.9M
↓ 0.44%
Net Income
-45.7M
↑ 18.01%
Net Profit Margin
-34.61%
↓ 5.41%
Q2 FY24Q/Q Change
Revenue
148.0M
↑ 12.22%
Net Income
-20.1M
↓ 55.97%
Net Profit Margin
-13.58%
↑ 21.03%
FY18Y/Y Change
Total Assets
119.7M
↓ 10.08%
Total Liabilities
65.3M
↑ 21.87%
FY19Y/Y Change
Total Assets
306.2M
↑ 155.79%
Total Liabilities
170.8M
↑ 161.61%
FY20Y/Y Change
Total Assets
511.7M
↑ 67.12%
Total Liabilities
170.1M
↓ 0.4%
FY21Y/Y Change
Total Assets
463.0M
↓ 9.53%
Total Liabilities
183.5M
↑ 7.83%
FY22Y/Y Change
Total Assets
448.2M
↓ 3.18%
Total Liabilities
208.4M
↑ 13.6%
FY23Y/Y Change
Total Assets
433.1M
↓ 3.36%
Total Liabilities
223.0M
↑ 7.02%
Q1 FY23Q/Q Change
Total Assets
421.7M
↓ 5.92%
Total Liabilities
199.9M
↓ 4.1%
Q2 FY23Q/Q Change
Total Assets
429.5M
↑ 1.85%
Total Liabilities
205.6M
↑ 2.87%
Q3 FY23Q/Q Change
Total Assets
439.8M
↑ 2.39%
Total Liabilities
220.0M
↑ 6.99%
Q4 FY23Q/Q Change
Total Assets
433.1M
↓ 1.51%
Total Liabilities
223.0M
↑ 1.4%
Q1 FY24Q/Q Change
Total Assets
909.8M
↑ 110.04%
Total Liabilities
819.5M
↑ 267.4%
Q2 FY24Q/Q Change
Total Assets
919.2M
↑ 1.04%
Total Liabilities
820.0M
↑ 0.06%
FY18Y/Y Change
Operating Cash Flow
-29.1M
↑ 94.94%
Investing Cash Flow
34.1M
↓ 198.37%
Financing Cash Flow
6.3M
↓ 3.51%
FY19Y/Y Change
Operating Cash Flow
-21.9M
↓ 24.79%
Investing Cash Flow
-89.3M
↓ 361.67%
Financing Cash Flow
111.6M
↑ 1670.2%
FY20Y/Y Change
Operating Cash Flow
-13.8M
↓ 37.07%
Investing Cash Flow
-132.4M
↑ 48.3%
Financing Cash Flow
214.3M
↑ 92.08%
FY21Y/Y Change
Operating Cash Flow
-37.8M
↑ 174.39%
Investing Cash Flow
105.3M
↓ 179.51%
Financing Cash Flow
-28.6M
↓ 113.33%
FY22Y/Y Change
Operating Cash Flow
-23.0M
↓ 39.05%
Investing Cash Flow
-52.4M
↓ 149.81%
Financing Cash Flow
26.7M
↓ 193.49%
Q1 FY23Q/Q Change
Operating Cash Flow
-30.8M
↓ 344.54%
Investing Cash Flow
3.8M
↓ 147.08%
Financing Cash Flow
905.0K
↓ 71.25%
Q2 FY23Q/Q Change
Operating Cash Flow
-4.6M
↓ 85.13%
Investing Cash Flow
9.0M
↑ 135.84%
Financing Cash Flow
4.4M
↑ 384.09%
Q3 FY23Q/Q Change
Operating Cash Flow
1.2M
↓ 126.16%
Investing Cash Flow
-15.4M
↓ 271.36%
Financing Cash Flow
66.0K
↓ 98.49%

Technicals Summary

Sell

Neutral

Buy

Irhythm Technologies, Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Irhythm Technologies, Inc.
Irhythm Technologies, Inc.
-5.17%
-39.82%
-30.2%
41.32%
-9.88%
Stryker Corporation
Stryker Corporation
10.1%
0.29%
23.96%
28.14%
65.26%
Boston Scientific Corp.
Boston Scientific Corp.
8.01%
20.6%
51.48%
79.3%
95.5%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
5.56%
-27.49%
-9.8%
-45.57%
-7.73%
Abbott Laboratories
Abbott Laboratories
3.74%
-5.87%
13.03%
-11.78%
35.19%
Medtronic Plc
Medtronic Plc
9.34%
5.59%
12.42%
-33.5%
-16.71%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Irhythm Technologies, Inc.
Irhythm Technologies, Inc.
NA
NA
0.0
-2.74
-0.81
-0.09
NA
3.18
Stryker Corporation
Stryker Corporation
39.84
39.84
2.64
12.0
0.19
0.07
0.01
51.86
Boston Scientific Corp.
Boston Scientific Corp.
66.34
66.34
2.01
2.41
0.09
0.05
NA
13.85
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
26.3
26.3
3.2
2.69
0.22
0.12
NA
12.35
Abbott Laboratories
Abbott Laboratories
35.92
35.92
4.16
4.66
0.14
0.06
0.02
22.6
Medtronic Plc
Medtronic Plc
30.16
30.16
1.66
5.2
0.08
0.04
0.03
37.39
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Irhythm Technologies, Inc.
Irhythm Technologies, Inc.
Buy
$2.1B
-9.88%
NA
-24.5%
Stryker Corporation
Stryker Corporation
Buy
$136.8B
65.26%
39.84
16.12%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$120.2B
95.5%
66.34
12.0%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$40.2B
-7.73%
26.3
23.74%
Abbott Laboratories
Abbott Laboratories
Buy
$198.1B
35.19%
35.92
13.65%
Medtronic Plc
Medtronic Plc
Buy
$115.3B
-16.71%
30.16
12.06%

Insights on Irhythm Technologies, Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 131.92M → 148.04M (in $), with an average increase of 10.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -45.66M → -20.10M (in $), with an average increase of 127.1% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 51.5% return, outperforming this stock by 81.7%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 79.3% return, outperforming this stock by 38.0%

Institutional Holdings

  • Vanguard Group Inc

    9.55%

  • Artisan Partners Limited Partnership

    8.60%

  • BlackRock Inc

    8.01%

  • Capital Research Global Investors

    7.99%

  • Sands Capital Management, LLC

    6.81%

  • Mackenzie Investments

    4.57%

Corporate Announcements

  • Irhythm Technologies, Inc. Earnings

    Irhythm Technologies, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

irhythm is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and machine- learning capabilities. our goal is to be the leading provider of first-line ambulatory electrocardiogram, or ecg, monitoring for patients at risk for arrhythmias. we have created a unique platform, zio by irhythm, which we believe allows physicians to diagnose many arrhythmias more quickly and efficiently than traditional technologies, avoiding multiple indeterminate tests, allowing for appropriate medical intervention and potentially avoiding more serious downstream medical events, including stroke.

Organization
Irhythm Technologies, Inc.
Employees
2000
CEO
Mr. Quentin S. Blackford
Industry
Health Technology

Discover More

FAQs